The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts Meeting Abstract


Authors: Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; Blouin, W.; Hancock, H.; Ganesan, N.; Galasso, N.; Marzouk, E.; Bahgat, A.; Jester, H.; Fong, S.; Butt, A.; Dogan, A.; Kim, Y. H.; Weinstock, D. M.
Abstract Title: The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837602061
PROVIDER: wos
Notes: Meeting Abstract: 683 -- Source: Wos
MSK Authors
  1. Steven M Horwitz
    364 Horwitz
  2. Alison Moskowitz
    148 Moskowitz
  3. Patricia Myskowski
    137 Myskowski
  4. Ahmet Dogan
    174 Dogan
  5. Theresa Davey
    3 Davey
  6. William Blouin
    1 Blouin
  7. Alexandra Bahgat
    1 Bahgat
Related MSK Work